Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B

Figure 3 Serum angiotensin-converting enzyme levels and liver fibrosis development in patients with chronic hepatitis B. A: Correlation between serum angiotensin-converting enzyme (ACE) level and liver fibrosis stage (F-Stage) (R = 0.42, R² = 0.181); B: Receiver operating characteristic curve analysis and area under curve (AUC) value for diagnostic performance of serum ACE level for predicting each stage of liver fibrosis. The optimal ACE level cut-off point for significant fibrosis was 12.8 U/L. Data are means ± SD, ^bP < 0.01.